tbuckley/cabot-search huggingface dataset:
An open-label, multicenter, expanded access study assessing the safety and efficacy of oral ruxolitinib administered to patients with primary myelofibrosis (PMF), post-polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).
Authors: Philipp D. le Coutre, Heinz Gisslinger, Pierre Zachee, Vikas Gupta, Jose Ricardo Perez, Nora Schenk, Suresh Vutukuru, Carmen Garcia-Hernandez, Renato Tavares, Monica Bocchia, Dietger Niederwieser
Journal: Journal of Clinical Oncology (2012)

TPS6640 Background: Myelofibrosis (MF) can be primary in origin or can progress from polycythemia vera (PPV-MF) or essential thrombocythemia (PET-MF). MF is characterized by cytopenias, reactive bone marrow fibrosis, splenomegaly, and constitutional symptoms including weight loss, fever, and night sweats. MF is associated with dysregulation of the Janus kinase pathway, irrespective of JAK2V617F mutation status. Recently, ruxolitinib (INCB018424) was approved for the treatment of MF on the basis of results from 2 phase 3 trials (COMFORT-I and -II). These trials demonstrated marked reductions in splenomegaly and symptom burden, and improvements in health-related quality of life (QoL) measures. Methods: JAK Inhibitor rUxolitinib in Myelofibrosis Patients (JUMP) is a global, phase 3b expanded access trial (NCT01493414) designed to assess the safety and efficacy of ruxolitinib in adult pts with PMF, PPV-MF or PET-MF who are treatment naïve, and are intolerant of, or had progressed on any prior therapy. Inclusion criteria: peripheral blast count of &lt;10%, adequate liver and renal function and intermediate-2 or high risk MF according to IPSS criteria or intermediate-1 risk MF with palpable spleen length ≥ 5 cm. The primary endpoint is to assess the safety of ruxolitinib. Additional endpoints include the proportion of pts with a &gt; 50% reduction in palpable spleen length, % change in white blood cell and platelet counts from baseline (BL), and change in packed red blood cell transfusion requirements. Changes from BL in QoL scores will be assessed using validated ECOG PS, FACT-Lymphoma, and FACIT instruments. Pts with a BL platelet count &gt; 200,000/μL will receive oral ruxolitinib 20 mg BID; pts with a BL platelet count of 100,000/μL to 200,000/μL will receive 15 mg BID; dose modifications are permitted for safety and efficacy. Global enrollment is open and currently includes 277 pts. This is planned to be the largest study ever conducted in pts with MF. [Table: see text]
The role of oophorectomy for colon cancer with ovarian metastasis
Authors: S. Lee, J. Lee, H. Ahn, J. Park, J. Kim, K. Park, H. Lim, W. Kang, B. Kim, Y. Park
Journal: Journal of Clinical Oncology (2009)

e15113 Background: A recent study demonstrated that colorectal cancer with ovarian metastases were less responsive to chemotherapy compared to extraovarian metastases. Hence, the ovary may actually represent a “sanctuary” for metastatic cells from CRC. The aim of the study was to investigate the impact of oophorectomy on survival of colorectal cancer patients with ovarian metastasis. Methods: Between 1996 and 2008, 83 colorectal cancer patients underwent oophorectomy. For the historical control, 47 colorectal cancer patients without oophorectomy were included in the analysis. Survival and its associated factors were analyzed using Kaplan-Meier method, log-rank test and Cox-regression analysis. Results: The median age was younger (48 years) in the oophorectomy group when compared to the historical control (54 years) (P =.012). The proportion of synchronous metastasis was higher in the oophorectomy than the control group (57% vs 30%, respectively; P=.003). After a median follow-up duration of 60.8 months (range, 7.4 - 169.7 months), the median OS was significantly longer in the oophorectomy group (28.1 vs 21.2 months, oophorectomy vs non-oophoreectomy; P=.038). For ovary-specific survival (date of ovarian metastasis diagnosis to death), colorectal cancer patients with oophorectomy showed significantly favorable survival than the control group (20.8 vs 10.9 months, respectively; P&lt;.001). At univariate analyses, no oophorectomy (P=.038), bilaterality of ovarian metastasis (P=0.032), the presence of extraovarian metastasis (P&lt;0.001), elevated CEA (p&lt;0.001), poor performance status (p=0.001), no palliative chemotherapy(p=0.001), no primary disease resection(p=0.005) were identified as significantly poor prognostic factors for overall survival. The no oophorectomy, no chemotherapy, extraovarian metastasis, elevated CEA, poor performance status retained statistical significance at multivariate level. (p=0.003, p=0.004, p=0.005, p=0.015, p=0.029, respectively). Conclusions: Based on this retrospective analysis, the oophorectomy significantly prolonged survival in colorectal cancer patients with ovarian metastases. A potential role of oophorectomy in the management of colorectal cancer should be prospectively studied. No significant financial relationships to disclose.
A multimodality endoscopic approach for the management of buried bumper syndrome
Authors: Nikolaos Lazaridis, Alberto Murino, Andrea Telese, Nikolaos Koukias, Edward J. Despott
Journal: Endoscopy (2019)

Buried bumper syndrome is a rare, long-term complication of percutaneous endoscopic gastrostomy (PEG) placement, occurring in 1 % – 2 % of cases [1] [2]. It is thought to occur because of prolonged compression of the tissue between the external and internal fixators, leading to ‘burying’ of the PEG bumper into the gastric wall ([Fig. 1]). Consequences include tube obstruction and, more rarely, bleeding, abscess formation, and perforation [1].
Fecal mutational load and distribution analysis in the non-invasive diagnois of colorectal cancer
Authors: G. Tarafa, I. Blanco, L. Casadomé, F. Mora, F. Vilardell, V. Moreno, P. Lizardi, J. Costa, G. Capellá
Journal: Journal of Clinical Oncology (2006)

3618 Background: Specific molecular profiles of exfoliated tumour cells may lead to non invasive diagnosis of cancer. We have developed a DNA chip-based methodology that allows for the simultaneous and quantitative detection of multiple allelic substitutions in bodily fluids. Total Mutational Load Distribution Analysis (MLDA) of DNA found in bodily fluids yields biometrics that may enable early tumor diagnosis. We wanted to ascertain whether the MLDA of selected K-ras and p53 mutations in fecal DNA distinguishes between absence of tumor and the presence of neoplastic disease and whether patients with adenomas can be distinguished from those bearing carcinomas. Method: DNA was obtained from solid stools or colonic lavage in 67 patients undergoing colonoscopy: non-neoplastic condition (n=24); adenomas (n=16); carcinomas in situ (n=6) and carcinomas (n=21). Quantitative and simultaneous detection of 8 substitutions at codons 12 and 13 of K-ras gene and 15 hotspots substitutions at exons 5 and 7 of p53 gene was performed using an oligonucleotide zip-code microarray with rolling circle amplification signal enhancement. Total Mutational Load (TML) and relative prevalence values of independent alleles were measured. Results: MLDA separated the three groups: Total Mutational Load (TML) of non-neoplastic conditions ranged from 5.3 to 7.15. TML of adenomas ranged from 16.50 to 22.24 and of carcinomas in situ from 22.30 to 36.29. TML of invasive carcinomas ranged from 25.06 to 67.9. In a training set of the first 40 samples analyzed a halfway cut-off value of 11.87 was established to discriminate between non-neoplastic and neoplastic disease. Sensitivity was 100% (95% CI 91.7–100) and specificity was 100% (95% CI 86.2- 100) in both sets. We have reproduced similar results with classic techniques like sequences and cloning. Conclusion: Stool MLDA appears to be a useful non-invasive marker of distal and proximal colonic neoplasms that deserves widespread validation. No significant financial relationships to disclose.
Zwitterionic amino acid-based Poly(ester urea)s suppress adhesion formation in a rat intra-abdominal cecal abrasion model
Authors: Nathan Z. Dreger, Zachary K. Zander, Yen-Hao Hsu, Derek Luong, Peiru Chen, Nancy Le, Trenton Parsell, Clause Søndergaard, Misha L. Dunbar, Nathan J. Koewler, Mark A. Suckow, Matthew L. Becker
Journal: Biomaterials (2019)
PET-Based Response after 2 Cycles of Brentuximab Vedotin in Combination with AVD for First-Line Treatment of Unfavorable Early-Stage Hodgkin Lymphoma: First Analysis of the Primary Endpoint of Breach, a Randomized Phase II Trial of Lysa-FIL-EORTC Intergroup
Authors: Luc-Matthieu Fornecker, Julien Lazarovici, Igor Aurer, Rene-Olivier Casasnovas, Anne-Claire Gac, Christophe Bonnet, Krimo Bouabdallah, Aurore Perrot, Lena Specht, Mohamed Touati, Jean Claude Eisenmann, Cecile Borel, Aspasia Stamatoullas, Emmanuelle Nicolas-Virelizier, Laurent Pascal, Pieternella Lugtenburg, Monica Bellei, Alexandra traverse-Glehen, Christiane Copie, Martin Hutchings, Annibale Versari, Michel Meignan, Massimo Federico, Marc Andre
Journal: Blood (2017)
Role of chemoradiotherapy in advanced biliary cancers.
Authors: Asha Nayak, Sameer Arora, Edward J. Kruse
Journal: Journal of Clinical Oncology (2012)

e14694 Background: Patients with metastatic biliary tract cancers have a poor outcome and radiotherapy is administered largely to patients with an intent of palliation. We analyzed our institutional biliary tract cancer database to compare the outcome between chemotherapy alone vs. chemoradiotherapy. Methods: From January 2005 to December 2010, 126 metastatic and inoperable biliary cancer patients were retrospectively analyzed. 59(46.8%) patients received chemoradiotherapy(CRT) and 67(53.1%) patients received chemotherapy alone. Chemotherapy regimens consisted of 5-fluorouracil, gemcitabine, or cisplatin. CRT patients received 3D-CRT with a median dose of 30 Gy (range, 25-35Gy ) at 1.8-2 Gy per fraction per day.Patients were categorized into Gall bladder, extrahepatic or intrahepatic bileduct cancers .The follow-up time was calculated from the time of diagnosis to the date of death or the last contact. Kaplan-Meier analysis was used to calculate the overall survival (OS). Results: Median OS was 6.6 months for all patients. Median OS was 6.9 months (0.8-26.0) for patients treated with chemotherapy alone and 10.2 months (0.8-46.9) for those treated with chemoradiotherapy (p = 0.002). Univariate survival analysis of categorical variables for patients treated with chemoradiotherapy revealed that age, race, gender, location of metastatic site, site of primary tumor ,T stage (T3 v. T4) or nodal stage were not significant. However, ECOG performance status (1 v. 2/3) and the dose of radiation (&lt;30 v. &gt;30 Gy) received were associated with improved survival (p = 0.002, p=0.032). Median OS was 13.2 months for ECOG 1 vs. 4.3 months for ECOG 2/3. Median OS was 12.3 months for patients treated with radiotherapy dose more than 30 Gy vs. 6.4 months for those who received less than 30 Gy. 12/59(20.3%) patients who received chemoradiotherapy lived approximately 2 years longer. Conclusions: Metastatic biliary tract cancer patients with good performance score may benefit from chemoradiotherapy, and this modality did not increase the mortality. Long-term survival was observed in this selected group.
Preoperative Topical Decolonization—An Additional Strategy to Reduce Oral Antibiotic Prophylaxis for Mohs Infections?
Authors: Harvey Smith, Kate Borchard, Carl Vinciullo
Journal: JAMA Dermatology (2019)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Dermatology HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Dermatology journal
An examination of medical and economic outcomes of U.S. veteran breast cancer patients.
Authors: Li Wang, Elyse Fritschel, Lu Li, Ahong Huang, Onur Baser
Journal: Journal of Clinical Oncology (2013)

e12010 Background: While a breast cancer diagnosis is common in many medical settings, it is still uncommon in the U.S. Department of Veterans Affairs (VA) population, namely due to the minority of female veterans and infrequent diagnosis among men (Neumayer L, Schifftner TL, Henderson WG, et al. Breast cancer surgery in Veterans Affairs and selected university medical centers: results of the patient safety in surgery study. J Am Coll Surg. 2007; 204(6): 1235-41.). Currently, few studies describe the outcomes of breast cancer patients in the VA population. Methods: Using the Veterans Health Administration (VHA) datasets, a retrospective, observational study of patients diagnosed with breast cancer during the study period from October 1, 2005 to September 30, 2010 was conducted. Mortality, health care resource use, and costs were assessed for the 12-month follow-up period. Patients' clinical characteristics were assessed descriptively, and mortality rates were calculated using the Kaplan-Meier method. Results: In patients identified with breast cancer (n=11,719), the total follow-up mortality rate reached 17.04% (n=1,993). Mortality by age stratum totaled 26.07% for patients 65 years and over (n=1,192), 10.64% for those age 40 to 64 years (n=711), and 20.22% (n=90) for patients under 39 years. Nearly one-fifth of all breast cancer patients had follow-up inpatient visits (19.00%), which translated into an average inpatient cost of $22,220 annually per patient. While a similar percentage of patients had follow-up emergency room (ER) visits (18.79%), the average ER cost per patient totaled $140.53 annually. Conclusions: Mortality rate is the lowest for U.S. veteran breast cancer patients between ages 40 and 64 and more than doubles for those over age 65. The mortality rate of patients under age 39 years also exceeded the rate of the 40-64 age group, leading to more years of potential life lost. Additionally, inpatient utilization contributes to a high average annual cost incurred by U.S. veteran breast cancer patients. This information may further aid physicians and researchers as the number of female veterans increases.
Ammonia Scavenging Prevents Progression of Fibrosis in Experimental Nonalcoholic Fatty Liver Disease
Authors: Francesco De Chiara, Karen Louise Thomsen, Abeba Habtesion, Helen Jones, Nathan Davies, Jordi Gracia‐Sancho, Nicolò Manicardi, Andrew Hall, Fausto Andreola, Hannah L. Paish, Lee H. Reed, Abigail A. Watson, Jack Leslie, Fiona Oakley, Krista Rombouts, Rajeshwar Prosad Mookerjee, Jelena Mann, Rajiv Jalan
Journal: Hepatology (2019)

In nonalcoholic fatty liver disease (NAFLD), fibrosis is the most important factor contributing to NAFLD-associated morbidity and mortality. Prevention of progression and reduction in fibrosis are the main aims of treatment. Even in early stages of NAFLD, hepatic and systemic hyperammonemia is evident. This is due to reduced urea synthesis; and as ammonia is known to activate hepatic stellate cells, we hypothesized that ammonia may be involved in the progression of fibrosis in NAFLD.In a high-fat, high-cholesterol diet-induced rodent model of NAFLD, we observed a progressive stepwise reduction in the expression and activity of urea cycle enzymes resulting in hyperammonemia, evidence of hepatic stellate cell activation, and progressive fibrosis. In primary, cultured hepatocytes and precision-cut liver slices we demonstrated increased gene expression of profibrogenic markers after lipid and/or ammonia exposure. Lowering of ammonia with the ammonia scavenger ornithine phenylacetate prevented hepatocyte cell death and significantly reduced the development of fibrosis both in vitro in the liver slices and in vivo in a rodent model. The prevention of fibrosis in the rodent model was associated with restoration of urea cycle enzyme activity and function, reduced hepatic ammonia, and markers of inflammation.The results of this study suggest that hepatic steatosis results in hyperammonemia, which is associated with progression of hepatic fibrosis. Reduction of ammonia levels prevented progression of fibrosis, providing a potential treatment for NAFLD.
Abstract 14926: Absence of Adventitial Vasa Vasorum Formation at the Coronary Segment With Myocardial Bridge -An Optical Coherence Tomography Study
Authors: Kensuke Nishimiya, Yasuharu Matsumoto, Hongxin Wang, Zhonglie Piao, Kazuma Ohyama, Hironori Uzuka, Kiyotaka Hao, Ryuji Tsuburaya, Jun Takahashi, Kenta Ito, Hiroaki Shimokawa
Journal: Circulation (2017)

Background: Myocardial bridge (MB) is a myocardial bundle through which coronary segment tunnels and could compress coronary arteries causing myocardial ischemia. However, the characteristic findin...
Potential Causes of False-Negative Interpretations in 68Ga-PSMA PET/CT for the Detection of Local and Recurrent Prostate Cancer
Authors: Derya Yakar, Walter Noordzij, Thomas C. Kwee
Journal: Clinical Nuclear Medicine (2019)

Abstract 68 Ga-PSMA PET/CT has emerged as a highly promising diagnostic method for the evaluation of prostate cancer. Although it is increasingly recognized that its specificity is imperfect, data on false-negatives in the prostate have been underreported. We present 3 cases with false-negatives for local (recurrent) prostate cancer on 68 Ga-PSMA PET/CT, using multiparametric MRI and histopathology as reference standard. Metal artifact of prostate gold markers placed for external beam radiation therapy, low level of PSMA uptake, and bladder spillover are potential causes of misinterpretation. Awareness of these diagnostic pitfalls may improve 68 Ga-PSMA PET/CT interpretation.
Phase Ib study of NGR-hTNF, a selective vascular targeting agent (VTA), in combination with cisplatin in patients with refractory solid tumors
Authors: G. Citterio, F. G. De Braud, V. Gregorc, T. M. De Pas, R. Scalamogna, S. Boselli, M. Giovannini, F. Caligaris-Cappio, A. Lambiase, C. Bordignon
Journal: Journal of Clinical Oncology (2009)

3570 Background: NGR-hTNF is a VTA exploiting a tumor-homing-peptide (NGR) that selectively binds to an aminopeptidase N/CD13 overexpressed on tumor blood vessels. In preclinical models, significant synergy between low-dose NGR-hTNF and cisplatin was shown. Methods: Patients with resistant/refractory solid tumors were treated with NGR-hTNF given with a low-dose, doubling-dose scheme (0.2–0.4–0.8–1.6 μg/m 2 ) as 1-hour intravenous infusion, in combination with cisplatin 80 mg/m 2 , both given every 3 weeks. A 3+3 escalation/de-escalation design was followed. PK sampling was performed after the first 3 cycles. DLT definition: any G3–4 toxicity related to NGR-hTNF. Results: 22 patients (median age: 60 years, range, 47–75; 14M/8F; ECOG PS 0/1 12/10) with different tumor types were evaluated over 77 cycles (range, 1–10). Median number of prior regimens was 3 (range, 1–6) and 12 patients (55%) were previously treated with platinum-based regimens. Both NGR-hTNF C max and AUC increased proportionally with dose. The combination was safe without PK interaction or exacerbation of platinum-associated toxicity profile. No shedding of soluble TNF receptors was observed up to 0.8 μg/m 2 . As expected for the low-dose range explored, MTD was not reached and no DLTs were registered at 0.2 μg/m 2 (n = 4), 0.4 μg/m 2 (n = 3) and 1.6 μg/m 2 (n = 3). At 0.8 μg/m 2 , a patient had a G3 transient acute infusion reaction. This cohort was expanded up to 6 patients for safety reasons, with no DLTs registered, and up to 12 patients, for preliminary activity evaluation. At this dose level of 0.8 μg/m 2 , two lung cancer patients, both pre-treated with platinum, achieved a partial response (-79%) and a significant tumor shrinkage (-28%) lasting 7.2 and 6.7 months, respectively, and an additional 4 patients experienced stable disease for a median duration of 6.4 months. The median progression-free survival for all patients (n = 22), for patients enrolled at 0.8 μg/m 2 (n = 12), and for patients pre-treated with platinum (n = 9) was 2.7, 4.7, and 4.3 months, respectively. Conclusions: The combination of NGR-hTNF 0.8 μg/m 2 with cisplatin 80 mg/m 2 shows a favourable toxicity profile and promising antitumor activity. [Table: see text]
Impact of Medicare Part D on out-of-pocket pharmaceutical costs for patients with cancer.
Authors: Sheetal Mehta Kircher, Michael Johansen, Caroline Richardson, Matthew M Davis
Journal: Journal of Clinical Oncology (2013)

6517 Background: As federal policy, Medicare Part D was designed to reduce OOP costs for Medicare beneficiaries, but the extent to which this occurred for patients with cancer has not been measured. The aim of this study is to quantify the impact of Part D eligibility on out-of-pocket (OOP) cost for prescription drugs for cancer patients. Methods: Differences-in-differences analyses were used to estimate the effects of Medicare Part D eligibility on OOP pharmaceutical costs, by comparing 4-year periods before and after Part D implementation. Analyses were based on data from the publicly available Medical Expenditure Panel Survey, a nationally representative, all-payer sample of the United States non-institutionalized civilian population. Our analysis compared per-capita OOP burden between Medicare beneficiaries (age 65+) with cancer to near-elderly patients age 55-64 years old with cancer. Statistical weights provided with the dataset were used to generate nationally representative estimates. Results: Overall, 2,147 near-elderly individuals with cancer and 5,296 individuals with Medicare and cancer were included in the analysis (total n=7,443), representing over 88 million people with cancer in 8 years of study. As expected, prescription drug coverage more than doubled among individuals with Medicare from before Part D (34.4%) to after (77.8%); in contrast, prescription drug coverage among the near-elderly remained stable before vs. after Part D (72.0% vs. 71.1%). The mean per-capita OOP cost for Medicare beneficiaries with cancer before Part D was $935 (SE ±30) and decreased to $616 (±25) after implementation of Medicare Part D—a decline of 34%. Compared with changes in OOP pharmaceutical costs for non-elderly patients with cancer over the same period, implementation of Medicare Part D was associated with a further reduction of $159 (±73) per person with cancer. Conclusions: The implementation of Medicare D has significantly reduced OOP prescription drug costs for seniors with cancer, beyond trends observed for younger patients. Further analyses will examine OOP cost patterns for patients with cancer with specific sociodemographic and clinical characteristics.